A QUALITATIVE ANALYSIS OF RECENT NEW HEALTH TECHNOLOGY ASSESSMENT CASES AND EVALUATION TRENDS FOR THE ADOPTION OF NOVEL TECHNOLOGIES
Author(s)
Jinhee Moon1, sungwon jung, PhD2;
1Vantive Korea Incorporated, Government Policy and Reimbursement, Korea, Republic of, 2Vantive, Seoul, Korea, Republic of
1Vantive Korea Incorporated, Government Policy and Reimbursement, Korea, Republic of, 2Vantive, Seoul, Korea, Republic of
OBJECTIVES: New Health Technology Assessment (nHTA) evaluates the safety and effectiveness of new medical technologies prior to their introduction into the Korea National Health Insurance system and is conducted by the National Evidence-based Healthcare Collaborating Agency (NECA). In the context of rapid technological advancement and evolving regulatory conditions, this study aimed to qualitatively analyze recent nHTA cases to identify trends in submitted technologies, evaluation outcomes, and implications for the adoption of advanced medical technologies.
METHODS: Publicly disclosed nHTA reports available on the NECA website were reviewed for technologies submitted between August 2023 and December 2025. The analysis focused on procedure- and intervention-related technologies and examined application status, evaluation outcomes, technological characteristics, and subcommittee specialty composition.
RESULTS: During the study period, 73 nHTA applications were submitted, of which 56 were completed and 17 remain under review. Among completed cases, 26 technologies were approved as new medical technologies, 22 were classified as research-stage technologies, and 8 were categorized as others, including rejection, withdrawal, or determination as existing technologies. An increasing proportion of approved technologies utilized imaging and robotic systems. Disease areas associated with submitted technologies were diverse; however, orthopedics, surgery, and radiology were most frequently represented, with review committees typically comprising multiple clinical specialties. Technologies approved as new medical technologies were supported by established clinical guidelines or robust evidence, whereas research-stage technologies demonstrated potential clinical usefulness but required higher levels of evidence.
CONCLUSIONS: Recent nHTA trends reflect growing adoption of imaging- and robot-assisted technologies and increasing multidisciplinary evaluation processes. These findings underscore the need for flexible assessment frameworks and structured evidence-generation pathways to support timely adoption of innovative medical technologies. Further research is warranted to clarify disease-specific evaluation trends and evidence development needs.
METHODS: Publicly disclosed nHTA reports available on the NECA website were reviewed for technologies submitted between August 2023 and December 2025. The analysis focused on procedure- and intervention-related technologies and examined application status, evaluation outcomes, technological characteristics, and subcommittee specialty composition.
RESULTS: During the study period, 73 nHTA applications were submitted, of which 56 were completed and 17 remain under review. Among completed cases, 26 technologies were approved as new medical technologies, 22 were classified as research-stage technologies, and 8 were categorized as others, including rejection, withdrawal, or determination as existing technologies. An increasing proportion of approved technologies utilized imaging and robotic systems. Disease areas associated with submitted technologies were diverse; however, orthopedics, surgery, and radiology were most frequently represented, with review committees typically comprising multiple clinical specialties. Technologies approved as new medical technologies were supported by established clinical guidelines or robust evidence, whereas research-stage technologies demonstrated potential clinical usefulness but required higher levels of evidence.
CONCLUSIONS: Recent nHTA trends reflect growing adoption of imaging- and robot-assisted technologies and increasing multidisciplinary evaluation processes. These findings underscore the need for flexible assessment frameworks and structured evidence-generation pathways to support timely adoption of innovative medical technologies. Further research is warranted to clarify disease-specific evaluation trends and evidence development needs.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
HTA72
Topic
Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes, Systems & Structure
Disease
No Additional Disease & Conditions/Specialized Treatment Areas